14.7% Average Loss With Tirzepatide in Type 2 Diabetes
SURMOUNT-2 found 14.7% average weight loss with tirzepatide 15 mg at 72 weeks in adults with type 2 diabetes, with study context and limits.
At week 72, mean body-weight change was −12.8% with tirzepatide 10 mg and −14.7% with 15 mg, versus −3.2% with placebo.
938 adults with BMI of at least 27 and type 2 diabetes, with baseline HbA1c from 7% to 10%; 72 weeks. Read the linked peer-reviewed source for the full methodology, findings, and limitations.